DK3894857T3 - Tomme porøse partikler til anvendelse ved behandling, forebyggelse og/eller udskydelse af degeneration af neurodegenerative sygdomme, neuroner og glia - Google Patents

Tomme porøse partikler til anvendelse ved behandling, forebyggelse og/eller udskydelse af degeneration af neurodegenerative sygdomme, neuroner og glia Download PDF

Info

Publication number
DK3894857T3
DK3894857T3 DK20719186.7T DK20719186T DK3894857T3 DK 3894857 T3 DK3894857 T3 DK 3894857T3 DK 20719186 T DK20719186 T DK 20719186T DK 3894857 T3 DK3894857 T3 DK 3894857T3
Authority
DK
Denmark
Prior art keywords
neurodegenerate
glia
neurons
degeneration
diseases
Prior art date
Application number
DK20719186.7T
Other languages
English (en)
Inventor
Adam Feiler
Elena Kozlova
Chunfang Zhou
Adrian Israelson
Varda Shoshan-Barmatz
Original Assignee
Nanologica Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanologica Ab filed Critical Nanologica Ab
Application granted granted Critical
Publication of DK3894857T3 publication Critical patent/DK3894857T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2878—Muscular dystrophy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
DK20719186.7T 2019-04-15 2020-04-15 Tomme porøse partikler til anvendelse ved behandling, forebyggelse og/eller udskydelse af degeneration af neurodegenerative sygdomme, neuroner og glia DK3894857T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1950470 2019-04-15
PCT/EP2020/060584 WO2020212418A1 (en) 2019-04-15 2020-04-15 Empty porous particles for use in treatment, prevention and/or postponement of degeneration of neurodegenerative diseases, neurons and glia.

Publications (1)

Publication Number Publication Date
DK3894857T3 true DK3894857T3 (da) 2022-11-07

Family

ID=70289415

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20719186.7T DK3894857T3 (da) 2019-04-15 2020-04-15 Tomme porøse partikler til anvendelse ved behandling, forebyggelse og/eller udskydelse af degeneration af neurodegenerative sygdomme, neuroner og glia

Country Status (11)

Country Link
US (1) US20220202716A1 (da)
EP (1) EP3894857B1 (da)
JP (1) JP2022529578A (da)
KR (1) KR20210153080A (da)
CN (1) CN113454456A (da)
AU (1) AU2020257990A1 (da)
CA (1) CA3130033A1 (da)
DK (1) DK3894857T3 (da)
ES (1) ES2932081T3 (da)
PL (1) PL3894857T3 (da)
WO (1) WO2020212418A1 (da)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154801A0 (en) * 2003-03-06 2003-10-31 Karotix Internat Ltd Multi-channel and multi-dimensional system and method
CN101878186A (zh) * 2007-11-30 2010-11-03 纳诺洛吉卡股份公司 用于制备有控制结构与粒度的纳米多孔氧化铝基材料的方法和利用所述方法获得的纳米多孔氧化铝
US9134327B2 (en) * 2008-06-30 2015-09-15 Biotechnology Research Corporation Limited STAT3 and TYK2 as drug targets for neurodegenerative diseases
EP2424498A1 (en) * 2009-04-29 2012-03-07 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
US20110223297A1 (en) * 2010-03-12 2011-09-15 Pepsico., Inc. Anti-Caking Agent for Flavored Products
DK2590661T3 (da) * 2010-07-06 2020-01-27 Nanologica Ab Forbedret fremgangsmåde til stamcelledifferentiering in vivo ved afgivelse af morfogener med mesoporøst siliciumdioxid og tilsvarende farmaceutisk aktive bestanddele
WO2012013617A2 (en) 2010-07-30 2012-02-02 Technische Universität Dortmund Polymeric complements to b-amyloid peptides
WO2012082237A1 (en) * 2010-10-26 2012-06-21 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Immunization with amyloid-beta oligomers
WO2012145428A2 (en) 2011-04-21 2012-10-26 Washington University Altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid
JP6421124B2 (ja) * 2012-11-06 2018-11-07 シグリッド・セラピューティクス・アーベー 医薬有効成分又は食品有効成分としての使用のための多孔質シリカ材料
WO2017153957A1 (en) * 2016-03-09 2017-09-14 Avita International Ltd. Stem cells expressing mesenchymal and neuronal markers, compositions thereof, and methods of preparation thereof
CN113813401A (zh) * 2013-11-05 2021-12-21 埃琳娜·莫洛卡诺瓦 用于调节受体和离子通道的位置特异性亚型的纳米结构轭合物
EP3267992A4 (en) * 2015-03-09 2018-12-05 Immune Modulation, Inc. Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases
CN108135848A (zh) * 2015-06-30 2018-06-08 纳米提克斯有限责任公司 与清除颗粒相关的组合物和方法
KR102129378B1 (ko) * 2017-07-27 2020-07-02 한국과학기술원 베타-아밀로이드 응집 억제용 업컨버젼 나노입자
CA3107349A1 (en) * 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders

Also Published As

Publication number Publication date
CA3130033A1 (en) 2020-10-22
KR20210153080A (ko) 2021-12-16
JP2022529578A (ja) 2022-06-23
PL3894857T3 (pl) 2023-01-09
EP3894857A1 (en) 2021-10-20
US20220202716A1 (en) 2022-06-30
EP3894857B1 (en) 2022-09-07
AU2020257990A1 (en) 2021-08-19
ES2932081T3 (es) 2023-01-11
CN113454456A (zh) 2021-09-28
WO2020212418A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
IL258846A (en) Nicotinamide for use in the treatment and prevention of optic neurodegenerative disorder
IL311136A (en) Anti-CD3 antibody for use in the treatment or prevention of cancer and molecules containing the antibody
ZA202100819B (en) Anti-btn3a antibodies and their use in treating cancer or infectious disorders
DK3484585T3 (da) Anvendelse af probiotika ved behandling og/eller forebyggelse af atopisk dermatitis
LT3270890T (lt) Ciklosporino vaisto formos, skirtos naudoti plaučių transplantato lėtinio atmetimo prevencijai arba gydymui
EP3463406A4 (en) COMPOSITIONS AND METHODS OF TREATMENT AGAINST LYTIC AND LYSOGENIC VIRUSES
DK3678692T3 (da) Genotypestratificering ved behandling og forebyggelse af diabetes
ZA202005807B (en) Modified filter membrane and method
PL3463469T3 (pl) Kombinacja ledipaswiru i sofosbuwiru do zastosowania w leczeniu zakażeń wirusem zapalenia wątroby typu b u ludzi
DK3271392T3 (da) Midler til anvendelse ved terapeutisk eller profylaktisk behandling af myopia eller hyperopia
PL3641795T3 (pl) Sposoby i materiały do leczenia naczyń krwionośnych
FR3026337B1 (fr) Procede de traitement de morceaux de bois et leur utilisation dans la fabrication de vins et de spiritueux, ou d'extraits de bois, ou de contenants en bois
DK3894857T3 (da) Tomme porøse partikler til anvendelse ved behandling, forebyggelse og/eller udskydelse af degeneration af neurodegenerative sygdomme, neuroner og glia
DK3360580T3 (da) Fremgangsmåde til genetisk behandling ved anvendelse af aav-xbp1s/gfp-virussen og anvendelse deraf i forebyggelsen og behandlingen af amyotrofisk lateral sklerose
DK3654932T3 (da) Tyrothricin til anvendelse ved behandling eller forebyggelse af kropslugt og præparater hertil
EP3372249C0 (en) AAV/UPR-PLUS VIRUS, UPR-PLUS FUSION PROTEIN, GENETIC TREATMENT METHOD AND USE THEREOF IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS PARKINSON'S DISEASE AND HUNTINGTON'S DISEASE
DK3810128T3 (da) Sammensætninger til behandling og/eller forebyggelse af proteinaggregeringssygdomme
RS64368B1 (sr) Postrojenje i postupak za tretman otpada, posebno otpada iz laboratorija za medicinsku analizu
IL259383A (en) A compound for use in the prevention and treatment of neurodegenerative diseases
EP3428179A4 (en) PEPTIDE FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES AND USE THEREOF
EP3261439A4 (en) METHOD AND MATERIALS FOR TREATING HUMAN IMMUNE WEAKAGE VIRUS INFECTIONS
DK3860582T3 (da) Forbindelser til anvendelse ved behandling eller forebyggelse af smerte, inflammation og/eller autoimmunitet
EP3265097A4 (en) Compositions and methods for treatment and prevention of pyrexia in horses
IL265595A (en) Small molecules that protect the WASP protein, preparations that include them and their use in methods for treating acquired or genetic diseases of the immune system
SG11202105740WA (en) Treated particles and substrates